NASDAQ$TELA
TELA Bio Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported financial results, demonstrating resilience and flexibility amidst pandemic challenges.
TELA Bio reported a 6% increase in revenue to $3.5 million for Q2 2020, with a gross profit of $2.1 million, or 59% of revenue. The company's operating expenses were $7.3 million, leading to a net loss of $6.1 million. Cash and cash equivalents totaled $85.5 million at the end of the quarter.
- Revenue increased by 6% compared to the prior year period, reaching $3.5 million.
- Gross profit was $2.1 million, representing 59% of revenue.
- Operating expenses increased to $7.3 million due to commercial expansion and public company costs.
- Cash and cash equivalents totaled $85.5 million.
Headline financials
Revenue & EPS history
TELA Bio · Revenue · Quarterly
$3.51M
Forward guidance
Due to the uncertainty caused by the COVID-19 pandemic, TELA Bio will not be providing 2020 financial guidance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2020
-2.5%
Avg return
Earnings day
-3.0%
Avg return
5 days after
+3.5%
Avg return
30 days after
42%
11 / 26 earnings
Positive
+20.2%
Q1 2024
Best reaction
-37.2%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.7% | -9.3% | — | |
| Q1 2026 | -5.3% | -18.6% | -15.7% | |
| Q3 2025 | -9.3% | -2.7% | +3.6% | |
| Q1 2025 | +7.2% | -0.1% | +90.7% | |
| Q4 2024 | -37.2% | -44.9% | -59.1% | |
| Q3 2024 | +2.0% | +3.0% | -1.7% | |
| Q2 2024 | -23.9% | -23.4% | -35.0% | |
| Q1 2024 | +20.2% | +21.2% | +16.7% | |
| Q4 2023 | +4.0% | +0.9% | -13.8% | |
| Q3 2023 | -20.3% | -21.7% | -4.5% | |
| Q2 2023 | -4.8% | -1.2% | -2.8% | |
| Q1 2023 | -3.6% | -4.8% | +11.2% | |
| Q4 2022 | -5.5% | -3.7% | -11.3% | |
| Q3 2022 | +13.8% | +11.2% | +44.7% | |
| Q2 2022 | -6.5% | +5.5% | +0.9% | |
| Q1 2022 | -5.7% | -7.0% | -31.4% | |
| Q4 2021 | -4.8% | -4.8% | -20.4% | |
| Q3 2021 | -3.8% | -3.7% | -1.7% | |
| Q2 2021 | +5.0% | +4.4% | -8.3% | |
| Q1 2021 | +3.2% | +11.5% | +5.9% | |
| Q4 2020 | -6.6% | +0.9% | -1.8% | |
| Q3 2020 | -3.5% | -0.8% | -3.6% | |
| Q2 2020 | +5.4% | +4.1% | +20.7% | |
| Q1 2020 | -2.4% | -3.6% | +38.6% | |
| Q4 2019 | +0.6% | -0.4% | +34.0% | |
| Q3 2019 | +13.9% | +8.8% | +32.6% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro